Bacterial Conjunctivitis Drugs Market in U.S. to Reach US$439.8 mn by 2024; Patent Expirations Could Adversely Impact Growth According to a new market report published by Transparency Market Research “Bacterial Conjunctivitis Drugs Market - U.S. Industry Analysis, Pipeline Assessment, Size, Share, Growth, Trends and Forecast 2012 - 2024� the bacterial conjunctivitis drugs market in the U.S. was valued at US$473.3 mn in 2013 and is estimated to reach a market worth of US$439.8 mn in 2024, at a CAGR of 2.7% from 2012 to 2018 and (-3.73%) from 2018 to 2024.
Conjunctivitis is an inflammation of the conjunctiva - the clear membrane that covers the outermost layer of an eye and the inner surface of eyelids. Conjunctivitis is segmented into three major categories: infective (viral and bacterial), allergic, and irritant (chemical). Bacterial conjunctivitis is one of the most commonly observed eye problems across all age groups, generally caused by bacteria such as Staphylococcus aureus, Moraxella lacunata, Haemophilus influenza, and others (e.g. Chlamydia trachomatis, Proteus mirabilis, etc.). As reported by Healio (specialty medical news and journal publisher), approximately 5 million acute bacterial conjunctivitis cases are reported in the U.S. each year. Thus, high prevalence of bacterial conjunctivitis in the country demands effective medications, thereby driving the growth of the bacterial conjunctivitis drugs market in the U.S. However, despite the increasing incidence of bacterial conjunctivitis, the overall bacterial conjunctivitis market in the U.S. is likely to witness negative growth due to the patent expirations of major blockbuster drugs such as Vigamox, Moxeza, Zymaxid, and Besivance in the next few years. Rise in ophthalmic bacterial infections is increasing the demand for antibacterial drugs in the U.S. According to a clinical study conducted by the scientists Amir A. Azari and Neal P. Barney, published in the Journal of the American Medical Association (JAMA) in 2013, bacterial conjunctivitis accounts for over 50% of the conjunctivitis cases in the U.S. It also quoted that the incidence of bacterial conjunctivitis was estimated to be 135 in 10,000 in a single study. These statistics indicate that the U.S. is witnessing high incidence of bacterial conjunctivitis, hence leading to increased demand for bacterial conjunctivitis drugs in the country. Read Full Report: http://www.transparencymarketresearch.com/us-bacterial-conjunctivitisdrugs-market.html Fluoroquinolones, aminoglycosides, macrolides and other antibacterials such as bacitracin, doxycycline, and ceftriaxone collectively form the bacterial conjunctivitis market; among which